The use of immune checkpoint inhibitor therapy for acute myeloid leukemia (AML) has progressed drastically over the past several years. Speaking from the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, updates us on the current landscape of this therapy for AML. Dr Daver highlights key data from the study of nivolumab plus azacitidine as a salvage therapy, which provided insights into the impact of T-cell numbers prior to therapy on response rates. He then moves on to discuss exciting data from more recent trials in the frontline setting, including azacitidine plus nivolumab (BMS-936558; NCT02397720) or durvalumab (MEDI4736; NCT02775903). To round-up the discussion, Dr Daver gives his perspective on potential future combinations.
Update on checkpoint inhibitor therapy for AML: salvage, frontline & azacitidine combination
